Pink Sheet is part of the Informa Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

AstraZeneca To Save $60 Mil. Through PDI Sales Rep Reduction

This article was originally published in The Pink Sheet Daily

Executive Summary

No cuts will be made to the in-house sales force, AstraZeneca says. The company maintains that the decision was not in response to Exanta "not approvable" letter or the halt in Iressa promotions.
Advertisement

Related Content

AstraZeneca Likely To Reduce Its Contract Sales Force, PDI Says
AstraZeneca Likely To Reduce Its Contract Sales Force, PDI Says
AstraZeneca Productivity Savings Unlikely To Be Sustained Into 2006
AstraZeneca Productivity Savings Unlikely To Be Sustained Into 2006
PDI Reducing Reliance On Top Pharma Clients
Rumors Of Big Pharma Sales Force Cuts Could Boost Smaller Contracts For Ventiv
Iressa Promotion Halted; AstraZeneca To Highlight Tarceva Survival Benefit
AstraZeneca’s Exanta “Not Approvable” At FDA
AstraZeneca’s Exanta “Not Approvable” At FDA
Novartis Ends PDI Contract

Topics

Advertisement
UsernamePublicRestriction

Register

PS061043

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel